Drug Profile
Research programme: leptin-based immunotherapeutics - Imperial College Innovations
Latest Information Update: 03 Sep 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Developer Imperial Innovations; Nonindustrial source
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Immunological disorders; Immunosuppression
Most Recent Events
- 29 Sep 1999 New profile
- 29 Sep 1999 Technology available for licensing from Imperial College Innovations (e-mail: innovations@ic.ac.uk)
- 29 Sep 1999 Preclinical development for Immunological disorders in United Kingdom (Unknown route)